Yunnan Baiyao's revenue increased year-on-year, and its net profit has reached several billion yuan. However, some netizens found that this company has been in a situation of increasing income without increasing profits. After careful understanding, it is known that the company's stock investment has a direct loss of 65.438+55.5 million yuan. These losses mainly come from stocks, such as Xiaomi Group, Tencent Holdings and Hengrui Pharma. If Yunnan Baiyao falls, they will lose money. Shareholders always look at the data. Yunnan Baiyao lost money, and naturally some people chose to give up, and its market value declined.

1. Yunnan Baiyao does not increase revenue.

Looking at a company's revenue growth mainly depends on quarterly data. According to related websites, Yunnan Baiyao grew year-on-year in the first three quarters, with a net profit of several billion yuan. However, the revenue in the third quarter was disproportionate to the net profit, which increased substantially year-on-year, but the net profit of shareholders decreased year-on-year. After investigation, it was found that the original investment in stock trading was disproportionately affected, and the loss of stock trading led to a decline in net profit. Because the amount is too large, it directly affects the company, and the market value is gradually decreasing.

2. Diversified development of the company

Now Yunnan Baiyao is not only a pharmaceutical company, but also an investment company. Xiaomi Group, Tencent Holdings and Hengrui Pharma, which we are familiar with, all have investments. However, we all know that investment is risky. Xiaomi Group, Yili and Hengrui Pharma alone caused losses of about 900 million yuan to Yunnan Baiyao, with a total investment loss of 65.438+555 million yuan. This is not a small number. Seeing such data, the company will definitely make more efforts in investment in the future.

3. Try to take a new path.

Now Yunnan Baiyao has invested more and more money in research and development. D with less money, it can't compare with the same competitors. When they explain this, they think that innovation and R&; The threshold of D is too high. Early research and development needs a lot of investment. Once successful, it may be imitated, and the value of the results will shrink. To this end, Yunnan Baiyao is trying to take a new path, and medical beauty is an important direction. They have started to open offline stores in various places. I wonder if this direction can bring new vitality to the company.